Sophie Steeland

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

James F. Howard, Vera Bril, Tuan Vu et al. · Frontiers in Neurology · 2024 · 71 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)

James F. Howard, Tuan Vu, George Li et al. · Neurotherapeutics · 2024 · 47 citations · Full text

Medicine, Endocrinology, Internal Medicine +6

Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis

Jeffrey T. Guptill, John W. Sleasman, Sophie Steeland et al. · Autoimmunity · 2022 · 42 citations · Full text

Veterinary Medicine, Immunology, Pharmacology +17

Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases

Kelly Gwathmey, Catherine M. Broome, Matthias Goebeler et al. · Expert Review of Clinical Immunology · 2025 · 18 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +11

Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models

Prajakta Warang, Gagandeep Singh, Mahan Moshir et al. · Human Vaccines & Immunotherapeutics · 2025 · 13 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17